This reference antibody, modeled after lecanemab, is used in preclinical research and immunoassays for Alzheimer’s disease. It specifically targets amyloid-beta protofibrils in the brain, aiding in the study of amyloid plaque reduction and the mechanisms of cognitive decline. By binding to aggregated amyloid-beta forms, it serves as a tool for evaluating therapeutic interventions that clear protofibrils before dense plaque formation. Commonly employed in immunotherapy research, it helps assess disease-modifying potential. Additionally, it functions as a reference standard to measure amyloid burden and validate assay efficacy in laboratory settings.